Skip to content
Biotechnology

CIL Announces Breakthrough in Benzene Recovery, Addressing Cost, Environmental, and Supply Challenges for OLED Display Manufacturers

Cambridge Isotope Laboratories, Inc. 2 mins read

TEWKSBURY, MA / ACCESSWIRE / December 12, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has successfully developed and implemented a game-changing benzene-d6 recovery program, addressing major pain points for manufacturers of organic light-emitting diode (OLED) displays. This innovative service reduces costs, minimizes environmental impact, and conserves scarce deuterium supplies.

OLED display producers rely heavily on deuterated benzene (benzene-d6) as a critical starting material in their synthesis processes. However, this results in significant quantities of depleted benzene-d6, which is no longer usable but still retains considerable deuterium value. The disposal of such depleted material poses environmental challenges and substantial expenses.

CIL's benzene-recovery program offers a transformative solution. Customers can now return their depleted benzene-d6 to CIL, where it undergoes a proprietary re-enrichment process to restore it to virgin material quality. This service is available at a significant cost savings compared to new benzene-d6, providing significant economic benefits.

Beyond the financial advantages, the program has far-reaching environmental and supply implications. It eliminates the need for costly disposal, reduces the demand on increasingly scarce deuterium (derived from heavy water, D2O) and conserves this vital resource for its growing applications in science, medical diagnostics, pharmaceuticals, and semiconductor production.

Recycling offers several sustainable benefits. It reduces pollution by releasing fewer chemicals into the environment. Recycling also saves energy, as reprocessing chemicals like benzene requires less energy than producing them from raw materials. This leads to lower greenhouse gas emissions, helping to combat climate change.

"This initiative underscores CIL's commitment to collaboration and innovation in addressing our customers' most pressing challenges," said Cliff Caldwell, CEO of CIL. "By recovering and re-enriching depleted benzene-d6, we create a circular economy approach that is both economically and environmentally sustainable. As the world's largest supplier of benzene-d6, we are uniquely positioned to deliver this groundbreaking service."

CIL's benzene recovery program is the result of 12 months of dedicated development, expansion, and rigorous testing to ensure reliable capacity and uncompromising quality. CIL invites interested parties to inquire about the program's details and how to participate.

About Cambridge Isotope Laboratories, Inc.

CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX, located in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com.

Contact Information

Crissy Krisko
[email protected]
1.978.269.1930

.

SOURCE: Cambridge Isotope Laboratories, Inc.



View the original press release on accesswire.com

More from this category

  • Biotechnology, Business Company News
  • 20/05/2025
  • 09:48
Jane Morgan Management

LTR Pharma Limited (ASX:LTP) Expands National Patient Access for Erectile Dysfunction Treatment via Pharmacy Network Rollout

Dysfunction Treatment via Pharmacy Network Rollout 20 May 2025 – Sydney, Australia | LTR Pharma has announced the expansion of patient access to its fast-acting erectile dysfunction (ED) treatment, SPONTAN®, via a nationwide rollout through pharmacies dispensing under the TGA’s Special Access Scheme (SAS) and Authorised Prescriber Scheme (APS). SPONTAN® will now be available at over 600 pharmacies across Australia, distributing via the TerryWhite Chemmart network, alongside Pharmacy Choice and healthSAVE. The milestone marks the commercial implementation of LTR Pharma’s national distribution partnership with Symbion and enhances physical access for patients with prescriptions from authorised healthcare professionals. Highlights: SPONTAN® will…

  • Contains:
  • Biotechnology, Business Company News
  • 14/05/2025
  • 09:33
Optiscan Imaging Limited (ASX:OIL)

Optiscan Imaging (ASX:OIL) Progresses Robotic Surgery Collaboration with Mayo Clinic

Optiscan and Mayo Clinic have combined to significantly advance the development of a digital confocal laser endomicroscopic imaging system for use in robotic surgery. Highlights Optiscan, in combination with the Mayo Clinic, has advanced the development of its digital confocal laser endomicroscopic imaging system for use in robotic surgery. This development project has evolved out of the Know-How Agreement signed by Optiscan and the Mayo Clinic in mid calendar year 2024. The milestones achieved to date in the Optiscan/Mayo Clinic robotic surgery collaboration cover all target deliverables at the 12-month anniversary of the Agreement. Both groups have focused on co-development…

  • Biotechnology
  • 12/05/2025
  • 14:18
Cleo Diagnostics Limited. ASX.COV

CLEO Advances Commercial Product Development with Completion of Alpha Testing

Highlights Completion of alpha testing using commercial prototypes of CLEO’s Ovarian Cancerpre-surgical triage assay kits Testing was conducted at CLEO’s laboratory and confirmed:– Robust…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.